Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for Huntingtin gene silencing across an in vitro BBB model

In conclusion, the CD platform is a promising option for delivery of siRNA-based therapeutics for HD with wider potential to treat other diseases with a genetically validated target in the central nervous system.PMID:34793942 | DOI:10.1016/j.ejpb.2021.11.003

Source: European Journal of Pharmaceutics and Biopharmaceutics - November 18, 2021 Category: Drugs & Pharmacology Authors: Monique C P Mendon ça Michael F Cronin John F Cryan Caitriona M O'Driscoll Source Type: research